0001209191-20-063931.txt : 20201216 0001209191-20-063931.hdr.sgml : 20201216 20201216210007 ACCESSION NUMBER: 0001209191-20-063931 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201215 FILED AS OF DATE: 20201216 DATE AS OF CHANGE: 20201216 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LO FRANCIS CENTRAL INDEX KEY: 0001780660 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38957 FILM NUMBER: 201394005 MAIL ADDRESS: STREET 1: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION STREET 2: 1551 EASTLAKE AVE E STE 200 CITY: SEATTLE STATE: WA ZIP: 98102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp CENTRAL INDEX KEY: 0001478320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 270907024 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-659-0067 MAIL ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: Adaptive TCR Corp DATE OF NAME CHANGE: 20091209 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-12-15 0 0001478320 Adaptive Biotechnologies Corp ADPT 0001780660 LO FRANCIS C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION 1551 EASTLAKE AVE E STE 200 SEATTLE WA 98102 0 1 0 0 Chief People Officer Common Stock 2020-12-15 4 M 0 2000 7.80 A 2000 D Common Stock 2020-12-15 4 S 0 1759 55.79 D 241 D Common Stock 2020-12-15 4 S 0 241 57.01 D 0 D Common Stock 2500 I By You Jin Lee (spouse) Stock Option (Right To Buy) 7.80 2020-12-15 4 M 0 2000 0.00 D 2029-05-06 Common Stock 2000 161000 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $55.545 to 56.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $57.00 to 57.05, inclusive. The options vested with respect to 1/4 of such shares on May 6, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. /s/ Francis Lo by Eric Billings, Attorney-in-Fact 2020-12-16